# Specialized Program Of Research Excellence (SPORE) in Leukemia.

> **NIH NIH P50** · WASHINGTON UNIVERSITY · 2022 · $2,127,879

## Abstract

ABSTRACT
The Washington University SPORE in Leukemia is a highly dynamic translational cancer research program that
focuses specifically on leukemias and myelodysplastic syndromes (MDS). We have assembled an outstanding
group of investigators with complementary expertise in basic and clinical leukemia research. In this SPORE, we
leverage expertise in cancer genomics, immunology, and hematopoiesis to develop innovative translational
research in leukemia. Our long-term goal is to develop novel biomarkers and treatments for leukemias and
myelodysplastic syndromes and to develop and promote innovative translational leukemia research. To achieve
these goals, the following specific aims are proposed.
 Aim 1. We will exploit institutional expertise in cancer genomics, immunology, and hematopoiesis to
develop novel biomarkers and treatments for leukemias and myelodysplastic syndromes. Basic research
at WUSM has led to the development of the following five translational research projects, all featuring innovative
investigator-initiated therapeutic trials for leukemias or MDS.
 · Project 1. Molecular determinants of decitabine responsiveness
 · Project 2. Targeted therapies for T cell acute lymphoblastic leukemia (T-ALL)
 · Project 3. Novel therapies for splicesome-mutant MDS
 · Project 4. Bi-specific antibody-based therapies for AML
 · Project 5. Memory-like NK cell augmented hematopoietic cell transplantation for AML
 Aim 2. We will enhance the infrastructure that supports translational leukemia research. This SPORE
will support the following Shared Research Resources: 1) Core A. Biospecimen Processing; 2) Core B.
Biostatistics; and 3) Core C. Administration.
 Aim 3. We will recruit and train new investigators in translational research. This SPORE will support
a Career Enhancement Program (CEP) to recruit and mentor new investigators in translational leukemia
research. The SPORE has established a successful minority post-baccalaureate training program. The SPORE
also will support a Developmental Research Program (DRP) to support innovative translational concepts.
 Aim 4. We will facilitate inter-SPORE collaboration. Four of the SPORE projects include multi-institutional
clinical trials, including three at other Leukemia SPORE institutions. We have established CEP educational
exchange and grant review programs with peer Leukemia SPORE institutions. We will continue to organize and
participate in joint meetings of Leukemia SPOREs at MD Anderson and Harvard.

## Key facts

- **NIH application ID:** 10439617
- **Project number:** 5P50CA171963-10
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Daniel C Link
- **Activity code:** P50 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,127,879
- **Award type:** 5
- **Project period:** 2013-09-03 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10439617

## Citation

> US National Institutes of Health, RePORTER application 10439617, Specialized Program Of Research Excellence (SPORE) in Leukemia. (5P50CA171963-10). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10439617. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*